Oncoceutics collaborates extensively with leading cancer institutions around the world. These collaborations explore the unique mechanisms and therapeutic potential of imipridones, and their ability to selectively target G-protein coupled receptors (GPCRs) in numerous malignancies and other diseases. Major cancer research centers, including Massachusetts General Hospital, Dana Farber Cancer Institute, Fox Chase Cancer Center, Rutgers Cancer Institute of New Jersey, the Cleveland Clinic and the MD Anderson Cancer Center,  are working with the company to explore the efficacy of ONC201 in clinical trials via a variety of grant-funded and collaborative mechanisms. In January 2015, Oncoceutics and MD Anderson Cancer Center entered into a strategic agreement that provides for a sharing of risk and potential commercialization of ONC201.

For partnership opportunities:
Lee Schalop, M.D.

For scientific collaborations:
Joshua Allen, Ph.D.